Buprenorphine HIV Care Integration Project

Completed · Not applicable

Conditions studied: HIV Infection, Opioid-Related Disorders

In brief

A007 is a randomized, two-arm study evaluating the effectiveness of standard drug addiction counseling with buprenorphine/naloxone to enhanced motivational drug counseling with buprenorphine/naloxone for the treatment for opioid addiction in an integrated and nonintegrated HIV care setting.

Key facts

Study ID

NCT00348868

Run by

University of Miami

People needed

10

Starts

2006-07-01

Expected to finish

2007-12-01

Last updated by the study team

2008-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV infection
• Receiving or seeking outpatient HIV care
• Seeking outpatient treatment for opioid dependence and be willing to take buprenorphine
• Meets DSM-IV criteria for opioid dependence, and be willing to stop illicit opioid use and be experiencing early symptoms of opioid withdrawal at the time that buprenorphine is given
• Men and women age ≥ 18 years
• Women of reproductive potential must have a negative serum or urine pregnancy test result available within 7 days prior to initiating buprenorphine
• Within 30 days: (SGOT), ALT (SGPT), and alkaline phosphatase <=5 X ULN, Total bilirubin <= 2.5 x ULN

You may not qualify if…

• Serious medical problem
• Acute and/or severe psychiatric conditions
• High dose methadone (>30 mg/day)
• Documented co-dependence on alcohol and/or benzodiazepines, barbiturates
• Chronic pain management requiring opioids
• Pregnancy or breast-feeding
• Imprisonment or involuntary incarceration in a medical facility for psychiatric or physical

Where it is running

• University of Miami AIDS Clinical Reserach Unit — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.